Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 205 articles:
HTML format



Single Articles


    July 2021

  1. Erratum to "Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL113
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33597.
    PubMed    


  2. KIM K, Maiti A, Loghavi S, Pourebrahim R, et al
    Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33689.
    PubMed     Abstract available


    June 2021
  3. VENUGOPAL S, Shoukier M, Konopleva M, Dinardo CD, et al
    Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.
    PubMed     Abstract available


  4. SAXENA K, Herbrich SM, Pemmaraju N, Kadia TM, et al
    A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
    Cancer. 2021 Jun 25. doi: 10.1002/cncr.33690.
    PubMed     Abstract available


  5. HOPPMANN AL, Chen Y, Landier W, Hageman L, et al
    Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.
    Cancer. 2021 Jun 23. doi: 10.1002/cncr.33760.
    PubMed     Abstract available


  6. SASAKI K, Kantarjian HM, Morita K, Short NJ, et al
    Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Cancer. 2021 Jun 17. doi: 10.1002/cncr.33655.
    PubMed     Abstract available


    May 2021
  7. NGUYEN HTK, Terao MA, Green DM, Pui CH, et al
    Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management.
    Cancer. 2021 May 25. doi: 10.1002/cncr.33609.
    PubMed     Abstract available


  8. BORTHAKUR G, Odenike O, Aldoss I, Rizzieri DA, et al
    A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Cancer. 2021 May 2. doi: 10.1002/cncr.33590.
    PubMed     Abstract available


    April 2021
  9. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Sasaki K, Masarova L, et al
    Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.
    Cancer. 2021 Apr 29. doi: 10.1002/cncr.33622.
    PubMed     Abstract available


  10. IIJIMA M, Liu W, Panetta JC, Hudson MM, et al
    Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy.
    Cancer. 2021 Apr 29. doi: 10.1002/cncr.33624.
    PubMed     Abstract available


  11. ALLEN OS, Kim N, Morillo J, Smith CB, et al
    Assessment of prognostic understanding, perceived goals of care, and quality of life in hospitalized patients with leukemia or multiple myeloma.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33599.
    PubMed     Abstract available


  12. JAMY OH, Godby R, Dhir A, Costa LJ, et al
    Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United States.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33593.
    PubMed     Abstract available


  13. PEMMARAJU N
    A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
    Cancer. 2021 Apr 23. doi: 10.1002/cncr.33594.
    PubMed    


  14. MORITA K, Kantarjian HM, Sasaki K, Issa GC, et al
    Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33539.
    PubMed     Abstract available


  15. CALDWELL KJ, Budhraja A, Opferman JT, Pui CH, et al
    Activity of venetoclax against relapsed acute undifferentiated leukemia.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33531.
    PubMed    


  16. SASAKI K, Ravandi F, Kadia TM, DiNardo CD, et al
    De novo acute myeloid leukemia: A population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017.
    Cancer. 2021 Apr 5. doi: 10.1002/cncr.33458.
    PubMed     Abstract available


  17. RAUSCH CR, DiNardo CD, Maiti A, Jammal NJ, et al
    Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33508.
    PubMed     Abstract available


  18. SASAKI K, Kantarjian HM, Short NJ, Samra B, et al
    Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
    Cancer. 2021 Apr 1. doi: 10.1002/cncr.33529.
    PubMed     Abstract available


    March 2021
  19. AMONOO HL, LeBlanc TW, Kavanaugh AR, Webb JA, et al
    Posttraumatic stress disorder (PTSD) symptoms in patients with acute myeloid leukemia (AML).
    Cancer. 2021 Mar 25. doi: 10.1002/cncr.33524.
    PubMed     Abstract available


  20. JABBOUR E, Sasaki K, Short NJ, Ravandi F, et al
    Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33469.
    PubMed     Abstract available


  21. NAGLER A, Labopin M, Koc Y, Angelucci E, et al
    Outcome of T-cell-replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Cancer. 2021 Mar 19. doi: 10.1002/cncr.33522.
    PubMed     Abstract available


  22. KANTARJIAN HM, Kadia TM, DiNardo CD, Welch MA, et al
    Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Cancer. 2021 Mar 18. doi: 10.1002/cncr.33477.
    PubMed     Abstract available


    February 2021
  23. VIVES S, Martinez-Cuadron D, Bergua Burgues J, Algarra L, et al
    A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
    Cancer. 2021 Feb 24. doi: 10.1002/cncr.33403.
    PubMed     Abstract available


    January 2021
  24. ORAN B, Saliba RM, Mehta RS, Alousi AM, et al
    Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome.
    Cancer. 2021 Jan 20. doi: 10.1002/cncr.33383.
    PubMed     Abstract available


  25. WOLFSON JA, Bhatia S, Ginsberg J, Becker LK, et al
    Expenditures among young adults with acute lymphoblastic leukemia by site of care.
    Cancer. 2021 Jan 19. doi: 10.1002/cncr.33413.
    PubMed     Abstract available


  26. ABOU DALLE I, Kantarjian HM, Ravandi F, Daver N, et al
    Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.
    Cancer. 2021 Jan 15. doi: 10.1002/cncr.33409.
    PubMed     Abstract available


    December 2020
  27. BORTHAKUR G, Ofran Y, Tallman MS, Foran J, et al
    BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
    Cancer. 2020 Dec 3. doi: 10.1002/cncr.33338.
    PubMed     Abstract available


  28. BADAR T, Szabo A, Dinner S, Liedtke M, et al
    Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2020 Dec 1. doi: 10.1002/cncr.33340.
    PubMed     Abstract available


    November 2020
  29. STOCK W, Martinelli G, Stelljes M, DeAngelo DJ, et al
    Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2020 Nov 24. doi: 10.1002/cncr.33321.
    PubMed     Abstract available


  30. TOPP MS, Gokbuget N, Zugmaier G, Stein AS, et al
    Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Cancer. 2020 Nov 3. doi: 10.1002/cncr.33298.
    PubMed     Abstract available


    October 2020
  31. SHOUKIER M, Kadia T, Konopleva M, Alotaibi AS, et al
    Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33293.
    PubMed     Abstract available


  32. SEYMOUR EK, Ruterbusch JJ, Winn AN, George JA, et al
    The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33267.
    PubMed     Abstract available


  33. BATTIPAGLIA G, Labopin M, Hamladji RM, Blaise D, et al
    Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Par
    Cancer. 2020 Oct 29. doi: 10.1002/cncr.33255.
    PubMed     Abstract available


  34. BORTHAKUR G, Martinelli G, Raffoux E, Chevallier P, et al
    Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Cancer. 2020 Oct 27. doi: 10.1002/cncr.33188.
    PubMed     Abstract available


  35. CAYSSIALS E, Torregrosa-Diaz J, Leleu X, Guilhot F, et al
    Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cancer. 2020 Oct 23. doi: 10.1002/cncr.33281.
    PubMed    


  36. CAMPIOTTI L, Suter MB, Dentali F
    Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cancer. 2020 Oct 23. doi: 10.1002/cncr.33282.
    PubMed    


  37. RICHARD MA, Brown AL, Belmont JW, Scheurer ME, et al
    Genetic variation in the body mass index of adult survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study and the St. Jude Lifetime Cohort.
    Cancer. 2020 Oct 13. doi: 10.1002/cncr.33258.
    PubMed     Abstract available


    September 2020
  38. ROTZ SJ, Wei W, Thomas SM, Hanna R, et al
    Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia.
    Cancer. 2020 Sep 10. doi: 10.1002/cncr.33175.
    PubMed     Abstract available


    August 2020
  39. KAROL SE, Cooper TM, Mead PE, Crews KR, et al
    Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia.
    Cancer. 2020 Aug 18. doi: 10.1002/cncr.33156.
    PubMed     Abstract available


  40. BLUM WG, Mims AS
    Treating acute myeloid leukemia in the modern era: A primer.
    Cancer. 2020 Aug 7. doi: 10.1002/cncr.32904.
    PubMed     Abstract available


    July 2020
  41. SOLEM CT, Bell TJ, Kwon Y, Cappelleri JC, et al
    A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemoth
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33072.
    PubMed     Abstract available


  42. KIM MS, Prasad V
    US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
    Cancer. 2020 Jul 9. doi: 10.1002/cncr.33058.
    PubMed     Abstract available


    May 2020
  43. PEIPERT JD, Yount SE, Efficace F, Loefgren C, et al
    Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy.
    Cancer. 2020 May 28. doi: 10.1002/cncr.32977.
    PubMed     Abstract available


  44. CAYSSIALS E, Torregrosa-Diaz J, Gallego-Hernanz P, Tartarin F, et al
    Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
    Cancer. 2020 May 27. doi: 10.1002/cncr.32940.
    PubMed     Abstract available


  45. ORAN B, Garcia-Manero G, Saliba RM, Alfayez M, et al
    Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
    Cancer. 2020;126:2193-2205.
    PubMed     Abstract available


  46. GILL HS, Yim R, Kumana CR, Tse E, et al
    Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators.
    Cancer. 2020 May 4. doi: 10.1002/cncr.32937.
    PubMed     Abstract available


    April 2020
  47. PRINTZ C
    Radiation from computed tomography scans is associated with increased risk for thyroid cancer and leukemia.
    Cancer. 2020;126:1601.
    PubMed    


  48. PRINTZ C
    Chemotherapy can induce relapse in some patients with leukemia.
    Cancer. 2020;126:1601.
    PubMed    


  49. RASHIDI A, Kaiser T, Graiziger C, Holtan SG, et al
    Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation.
    Cancer. 2020;126:1434-1447.
    PubMed     Abstract available


    March 2020
  50. GARRETT-MAYER E
    Geographically distributed data should be analyzed with spatial epidemiologic methods.
    Cancer. 2020;126:1161-1162.
    PubMed    


  51. PALANDRI F, Breccia M, Bonifacio M, Polverelli N, et al
    Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
    Cancer. 2020;126:1243-1252.
    PubMed     Abstract available


  52. RAUSCH CR, Jabbour EJ, Kantarjian HM, Kadia TM, et al
    Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management.
    Cancer. 2020;126:1152-1160.
    PubMed    


    February 2020
  53. YALNIZ FF, Patel KP, Bashir Q, Marin D, et al
    Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Cancer. 2020 Feb 26. doi: 10.1002/cncr.32769.
    PubMed     Abstract available


    January 2020
  54. MASAROVA L, Cortes JE, Patel KP, O'Brien S, et al
    Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32623.
    PubMed     Abstract available


  55. MAITI A, Cortes JE, Patel KP, Masarova L, et al
    Long-term results of frontline dasatinib in chronic myeloid leukemia.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32627.
    PubMed     Abstract available


  56. PRINTZ C
    Two-drug combination benefits patients with chronic lymphocytic leukemia.
    Cancer. 2020;126:13.
    PubMed    


  57. PRINTZ C
    First person profile: Ching-Hon Pui, MD: An internationally renowned pediatric oncologist, Dr. Pui helped to push the cure rate for pediatric acute lymphoblastic leukemia to more than 90.
    Cancer. 2020;127:9-10.
    PubMed    


    December 2019
  58. GHAZAWI FM, Ramanakumar AV, Alakel A, Lagace F, et al
    Incidence of acute myeloid leukemia: A regional analysis of Canada.
    Cancer. 2019 Dec 24. doi: 10.1002/cncr.32671.
    PubMed    


  59. NORWOOD TA, Seliske LM, De P
    Mapping the occurrence of acute myeloid leukemia: Methodological limitations and future direction.
    Cancer. 2019 Dec 24. doi: 10.1002/cncr.32673.
    PubMed    


  60. RANADE S, Palleschi C, Hirji MM, Spruyt M, et al
    Methodological rigor lacking in an analysis of acute myeloid leukemia incidence and geographic distribution in Canada.
    Cancer. 2019 Dec 24. doi: 10.1002/cncr.32674.
    PubMed    


  61. NARAYAN R, Blonquist TM, Emadi A, Hasserjian RP, et al
    A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Cancer. 2019 Dec 20. doi: 10.1002/cncr.32657.
    PubMed     Abstract available


  62. PRINTZ C
    Childhood leukemia could be a target for immunotherapy.
    Cancer. 2019;125:4345.
    PubMed    


    November 2019
  63. GORIN NC, Labopin M, Blaise D, de Groot M, et al
    Stem cell transplantation from a haploidentical donor versus a genoidentical sister for adult male patients with acute myelogenous leukemia in first remission: A retrospective study from the acute leukemia working party of the European Society for Blo
    Cancer. 2019 Nov 27. doi: 10.1002/cncr.32629.
    PubMed     Abstract available


  64. SHAH UA, Shah N, Qiao B, Acuna-Villaorduna A, et al
    Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32556.
    PubMed     Abstract available


  65. SASAKI K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, et al
    Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32566.
    PubMed     Abstract available


  66. WILLIAMS HE, Howell CR, Chemaitilly W, Wilson CL, et al
    Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude lifetime cohort study.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32596.
    PubMed     Abstract available


  67. YILMAZ U, Eskazan AE
    Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32608.
    PubMed    


  68. CHEN X, Hong Y, Zheng P, You X, et al
    The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32519.
    PubMed     Abstract available


    October 2019
  69. ORGEL E, Alexander TB, Wood BL, Kahwash SB, et al
    Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.
    Cancer. 2019 Oct 29. doi: 10.1002/cncr.32552.
    PubMed     Abstract available


  70. PHILLIPS NS, Howell CR, Lanctot JQ, Partin RE, et al
    Physical fitness and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime cohort.
    Cancer. 2019 Oct 21. doi: 10.1002/cncr.32510.
    PubMed     Abstract available


  71. RAMBALDI A, Ribera JM, Kantarjian HM, Dombret H, et al
    Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Cancer. 2019 Oct 18. doi: 10.1002/cncr.32558.
    PubMed     Abstract available


  72. CASSADAY RD
    When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.
    Cancer. 2019 Oct 18. doi: 10.1002/cncr.32565.
    PubMed    


  73. ZHANG C, Lam SSY, Leung GMK, Tsui SP, et al
    Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Cancer. 2019 Oct 3. doi: 10.1002/cncr.32534.
    PubMed     Abstract available


    September 2019
  74. JIM HSL, Hyland KA, Nelson AM, Pinilla-Ibarz J, et al
    Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial.
    Cancer. 2019 Sep 25. doi: 10.1002/cncr.32521.
    PubMed     Abstract available


  75. NAQVI K, Jabbour E, Skinner J, Anderson K, et al
    Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Cancer. 2019 Sep 25. doi: 10.1002/cncr.32504.
    PubMed     Abstract available


  76. BLOOMHARDT HM, Sint K, Ross WL, Rotatori J, et al
    Severity of reduced bone mineral density and risk of fractures in long-term survivors of childhood leukemia and lymphoma undergoing guideline-recommended surveillance for bone health.
    Cancer. 2019 Sep 19. doi: 10.1002/cncr.32512.
    PubMed     Abstract available


  77. ZEIDAN AM, Podoltsev NA, Wang X, Bewersdorf JP, et al
    Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis.
    Cancer. 2019 Sep 4. doi: 10.1002/cncr.32439.
    PubMed     Abstract available


    August 2019
  78. JABBOUR EJ, Gokbuget N, Kantarjian HM, Thomas X, et al
    Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
    Cancer. 2019 Aug 21. doi: 10.1002/cncr.32335.
    PubMed     Abstract available


  79. WU J, Chen Y, Hageman L, Francisco L, et al
    Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
    Cancer. 2019 Aug 14. doi: 10.1002/cncr.32443.
    PubMed     Abstract available


  80. MONTSERRAT E, Gale RP
    Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty.
    Cancer. 2019 Aug 5. doi: 10.1002/cncr.32353.
    PubMed     Abstract available


    July 2019
  81. BOULET-CRAIG A, Robaey P, Barlaam F, Laniel J, et al
    Visual short-term memory activation patterns in adult survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2019 Jul 16. doi: 10.1002/cncr.32374.
    PubMed     Abstract available


  82. SASAKI K, Kantarjian HM, Kadia T, Patel K, et al
    Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
    Cancer. 2019 Jul 16. doi: 10.1002/cncr.32387.
    PubMed     Abstract available


  83. SLAVIN SD, Fenech A, Jankowski AL, Abel GA, et al
    Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission.
    Cancer. 2019 Jul 12. doi: 10.1002/cncr.32397.
    PubMed     Abstract available


  84. PERCIVAL MM, Estey EH
    Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
    Cancer. 2019 Jul 10. doi: 10.1002/cncr.32354.
    PubMed     Abstract available


    June 2019
  85. SHOUVAL R, Labopin M, Gorin NC, Bomze D, et al
    Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia.
    Cancer. 2019 Jun 21. doi: 10.1002/cncr.32344.
    PubMed     Abstract available


  86. PRINTZ C
    States that expanded medicaid coverage note increased patient use of hormonal therapies.
    Cancer. 2019;125:1767.
    PubMed    


    May 2019
  87. CHAMOUN K, Kantarjian HM, Wang X, Naqvi K, et al
    Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.
    Cancer. 2019 May 31. doi: 10.1002/cncr.32196.
    PubMed     Abstract available


  88. GILL H, Kumana CR, Yim R, Hwang YY, et al
    Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
    Cancer. 2019 May 15. doi: 10.1002/cncr.32180.
    PubMed     Abstract available


    April 2019
  89. EL EIT R, Itani AR, Nassar F, Rasbieh N, et al
    Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    Cancer. 2019 Apr 29. doi: 10.1002/cncr.32130.
    PubMed     Abstract available


  90. RIBERA JM, Garcia O, Moreno MJ, Barba P, et al
    Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.
    Cancer. 2019 Apr 23. doi: 10.1002/cncr.32156.
    PubMed     Abstract available


  91. JABBOUR EJ, Sasaki K, Ravandi F, Short NJ, et al
    Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblas
    Cancer. 2019 Apr 15. doi: 10.1002/cncr.32139.
    PubMed     Abstract available


  92. KENZIK KM, Bhatia R, Williams GR, Bhatia S, et al
    Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
    Cancer. 2019 Apr 11. doi: 10.1002/cncr.32137.
    PubMed     Abstract available


    March 2019
  93. KANTARJIAN HM, DeAngelo DJ, Stelljes M, Liedtke M, et al
    Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Cancer. 2019 Mar 28. doi: 10.1002/cncr.32116.
    PubMed     Abstract available


  94. VANDSEMB EN, Kim TK, Zeidan AM
    Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?
    Cancer. 2019 Mar 12. doi: 10.1002/cncr.32042.
    PubMed    


    February 2019
  95. BENTON CB, Boddu PC, DiNardo CD, Bose P, et al
    Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.31986.
    PubMed     Abstract available


  96. GHAZAWI FM, Le M, Cyr J, Netchiporouk E, et al
    Analysis of acute myeloid leukemia incidence and geographic distribution in Canada from 1992 to 2010 reveals disease clusters in Sarnia and other industrial US border cities in Ontario.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32034.
    PubMed     Abstract available


  97. SAMET JM, Cockburn M
    What can be learned from mapping the occurrence of acute myeloid leukemia?
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32031.
    PubMed    


  98. SHARMA S, Rai KR
    Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
    Cancer. 2019 Feb 26. doi: 10.1002/cncr.31931.
    PubMed     Abstract available


  99. PRINTZ C
    Neurotoxicity more likely in Hispanic children treated for acute lymphoblastic leukemia.
    Cancer. 2019;125:494-495.
    PubMed    


  100. D'ADDA M, Farina M, Schieppati F, Borlenghi E, et al
    The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    Cancer. 2019 Feb 1. doi: 10.1002/cncr.31977.
    PubMed     Abstract available


    January 2019
  101. KRULL KR, Li C, Phillips NS, Cheung YT, et al
    Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2019 Jan 28. doi: 10.1002/cncr.31975.
    PubMed     Abstract available


  102. KANTARJIAN HM, Jabbour EJ, Garcia-Manero G, Kadia TM, et al
    Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
    Cancer. 2019 Jan 22. doi: 10.1002/cncr.31923.
    PubMed     Abstract available


  103. SANTORO N, Labopin M, Ciceri F, Van Lint MT, et al
    Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia over 45 years of age.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31941.
    PubMed     Abstract available


    December 2018
  104. CHIARETTI S, Messina M, Foa R
    BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31848.
    PubMed     Abstract available


  105. CALIP GS, Moran KM, Sweiss KI, Patel PR, et al
    Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
    Cancer. 2018 Dec 12. doi: 10.1002/cncr.31914.
    PubMed     Abstract available


  106. BODDU PC, Kadia TM, Garcia-Manero G, Cortes J, et al
    Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31885.
    PubMed     Abstract available


  107. YOON JH, Min GJ, Park SS, Jeon YW, et al
    Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31874.
    PubMed     Abstract available


  108. KANAGAL-SHAMANNA R, Jain P, Patel KP, Routbort M, et al
    Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
    Cancer. 2018 Dec 3. doi: 10.1002/cncr.31831.
    PubMed     Abstract available


    November 2018
  109. WILLIAMS P, Basu S, Garcia-Manero G, Hourigan CS, et al
    The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
    Cancer. 2018 Nov 30. doi: 10.1002/cncr.31896.
    PubMed     Abstract available


  110. SIMONETTI G, Padella A, do Valle IF, Fontana MC, et al
    Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
    Cancer. 2018 Nov 27. doi: 10.1002/cncr.31837.
    PubMed     Abstract available


  111. KLIL-DRORI AJ, Yin H, Azoulay L, Del Corpo A, et al
    Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31835.
    PubMed     Abstract available


  112. BRUNNER AM, Neuberg DS, Wander SA, Sadrzadeh H, et al
    Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31729.
    PubMed     Abstract available


    October 2018
  113. BROWNE EK, Zhou Y, Chemaitilly W, Panetta JC, et al
    Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia.
    Cancer. 2018 Oct 25. doi: 10.1002/cncr.31736.
    PubMed     Abstract available


  114. BAILEY C, Richardson LC, Allemani C, Bonaventure A, et al
    Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients diagnosed during 1995-2009.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31674.
    PubMed     Abstract available


  115. SEYMOUR EK, Ruterbusch JJ, Beebe-Dimmer JL, Schiffer CA, et al
    Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31738.
    PubMed     Abstract available


  116. MINA R, Joseph NS, Kaufman JL, Gupta VA, et al
    Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Cancer. 2018 Oct 17. doi: 10.1002/cncr.31718.
    PubMed     Abstract available


  117. HIDALGO-LOMICRONPEZ JE, Kanagal-Shamanna R, Quesada AE, Gong Z, et al
    Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.
    Cancer. 2018 Oct 15. doi: 10.1002/cncr.31663.
    PubMed     Abstract available


  118. JABBOUR E, Sasaki K, Ravandi F, Huang X, et al
    Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Cancer. 2018 Oct 11. doi: 10.1002/cncr.31720.
    PubMed     Abstract available


  119. PUI CH
    To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiation.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31756.
    PubMed    


  120. YEH TC, Liang DC, Hou JY, Jaing TH, et al
    Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.
    Cancer. 2018 Oct 10. doi: 10.1002/cncr.31758.
    PubMed     Abstract available


  121. TRUONG TH, Pole JD, Barber R, Dix D, et al
    Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population-based study.
    Cancer. 2018 Oct 6. doi: 10.1002/cncr.31728.
    PubMed     Abstract available


  122. NAQVI K, Kantarjian HM
    Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
    Cancer. 2018 Oct 1. doi: 10.1002/cncr.31683.
    PubMed    


  123. ESKAZAN AE
    Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
    Cancer. 2018 Oct 1. doi: 10.1002/cncr.31682.
    PubMed    


    June 2018
  124. ZHANG Y, Wang F, Chen X, Zhang Y, et al
    CSF3R mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Cancer. 2018 Jun 22. doi: 10.1002/cncr.31586.
    PubMed     Abstract available


  125. PRINTZ C
    First person: Hagop Kantarjian, MD: MD Anderson physician reflects on decades of leading research into new leukemia drugs.
    Cancer. 2018;124:2469.
    PubMed    


    May 2018
  126. ARELLANO M, Carlisle JW
    How I treat older patients with acute myeloid leukemia.
    Cancer. 2018 May 29. doi: 10.1002/cncr.31347.
    PubMed    


  127. GORDON MJ, Churnetski M, Alqahtani H, Rivera X, et al
    Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
    Cancer. 2018 May 24. doi: 10.1002/cncr.31554.
    PubMed     Abstract available



  128. Erratum: Fathi AT, Blonquist TM, Hernandez D, et al. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018;124:306-314.
    Cancer. 2018;124:2258.
    PubMed    


  129. PRINTZ C
    First person: John Byrd, MD: This Ohio State University researcher has been developing transformative treatments for patients with chronic lymphocytic leukemia, and now is setting his sights on individuals with acute myeloid leukemia.
    Cancer. 2018;124:2069.
    PubMed    


  130. ANDERSEN BL, Goyal NG, Weiss DM, Westbrook TD, et al
    Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia.
    Cancer. 2018 May 14. doi: 10.1002/cncr.31538.
    PubMed     Abstract available


  131. REA D, Ame S, Berger M, Cayuela JM, et al
    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31411.
    PubMed     Abstract available


  132. NAQVI K, Jabbour E, Skinner J, Yilmaz M, et al
    Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31357.
    PubMed     Abstract available


    April 2018
  133. ARTS LPJ, Oerlemans S, Tick L, Koster A, et al
    More frequent use of health care services among distressed compared with nondistressed survivors of lymphoma and chronic lymphocytic leukemia: Results from the population-based PROFILES registry.
    Cancer. 2018 Apr 26. doi: 10.1002/cncr.31410.
    PubMed     Abstract available


  134. ERCALISKAN A, Eskazan AE
    The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Cancer. 2018 Apr 25. doi: 10.1002/cncr.31408.
    PubMed     Abstract available


  135. ASSI R, Kantarjian HM, Kadia TM, Pemmaraju N, et al
    Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31398.
    PubMed     Abstract available


  136. KANTARJIAN HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, et al
    Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31370.
    PubMed     Abstract available


  137. DINARDO CD, Routbort MJ, Bannon SA, Benton CB, et al
    Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31331.
    PubMed     Abstract available


    March 2018
  138. CZERW T, Labopin M, Giebel S, Socie G, et al
    Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemi
    Cancer. 2018 Mar 30. doi: 10.1002/cncr.31354.
    PubMed     Abstract available


  139. GILL H, Yim R, Lee HKK, Mak V, et al
    Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31327.
    PubMed     Abstract available


  140. XUAN L, Wang Y, Huang F, Jiang E, et al
    Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31295.
    PubMed     Abstract available


  141. KANTARJIAN HM, Su Y, Jabbour EJ, Bhattacharyya H, et al
    Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31317.
    PubMed     Abstract available


  142. EFFICACE F, Castagnetti F, Martino B, Breccia M, et al
    Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31323.
    PubMed     Abstract available


    February 2018
  143. CIUREA SO, Labopin M, Socie G, Volin L, et al
    Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Cancer. 2018 Feb 22. doi: 10.1002/cncr.31311.
    PubMed     Abstract available


  144. SESTILI S, Labopin M, Ruggeri A, Velardi A, et al
    T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT).
    Cancer. 2018 Feb 22. doi: 10.1002/cncr.31310.
    PubMed     Abstract available


  145. HO G, Wun T, Muffly L, Li Q, et al
    Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.31296.
    PubMed     Abstract available


  146. PRINTZ C
    First person: Ali Bazarbachi, MD, PhD: The professor at the American University of Beirut has advanced the treatment of leukemia and cancer research in the Middle East and worldwide.
    Cancer. 2018;124:661-662.
    PubMed    


    January 2018
  147. JABBOUR EJ, DeAngelo DJ, Stelljes M, Stock W, et al
    Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
    Cancer. 2018 Jan 30. doi: 10.1002/cncr.31249.
    PubMed     Abstract available


  148. TALPAZ M, Saglio G, Atallah E, Rousselot P, et al
    Dasatinib dose management for the treatment of chronic myeloid leukemia.
    Cancer. 2018 Jan 25. doi: 10.1002/cncr.31232.
    PubMed     Abstract available


  149. RUGGERI A, Labopin M, Bacigalupo A, Gulbas Z, et al
    Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide.
    Cancer. 2018 Jan 23. doi: 10.1002/cncr.31228.
    PubMed     Abstract available


    December 2017
  150. BALTZELL KA, Shen HM, Krishnamurty S, Sison JD, et al
    Bovine leukemia virus linked to breast cancer but not coinfection with human papillomavirus: Case-control study of women in Texas.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31169.
    PubMed     Abstract available


  151. SASAKI K, Kantarjian H, O'Brien S, Ravandi F, et al
    Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31187.
    PubMed     Abstract available


  152. SALZER WL, Burke MJ, Devidas M, Chen S, et al
    Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31099.
    PubMed     Abstract available


  153. INABA H, Cao X, Han AQ, Panetta JC, et al
    Bone mineral density in children with acute lymphoblastic leukemia.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31184.
    PubMed     Abstract available


  154. TAI EW, Ward KC, Bonaventure A, Siegel DA, et al
    Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5178-5189.
    PubMed     Abstract available


  155. ABAZA YM, Kadia TM, Jabbour EJ, Konopleva MY, et al
    Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
    Cancer. 2017;123:4851-4859.
    PubMed     Abstract available


  156. ROSENSTOCK AS, Niu J, Giordano SH, Zhao H, et al
    Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Cancer. 2017 Dec 13. doi: 10.1002/cncr.31144.
    PubMed     Abstract available


  157. MARRIOTT CJC, Beaumont LF, Farncombe TH, Cranston AN, et al
    Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31191.
    PubMed     Abstract available


  158. ROBOZ GJ, Kantarjian HM, Yee KWL, Kropf PL, et al
    Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31138.
    PubMed     Abstract available


  159. SCHIFFER CA
    "Epigenetic" modification as therapy for acute myeloid leukemia.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31137.
    PubMed    


  160. HOWELL CR, Wilson CL, Ehrhardt MJ, Partin RE, et al
    Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study.
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31162.
    PubMed     Abstract available


  161. NEUKIRCHEN J, Lauseker M, Hildebrandt B, Nolting AC, et al
    Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
    Cancer. 2017;123:4608-4616.
    PubMed     Abstract available


    November 2017
  162. ZHENG DJ, Lu X, Schore RJ, Balsamo L, et al
    Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31085.
    PubMed     Abstract available


  163. GOLDSBY RE, Stratton KL, Raber S, Ablin A, et al
    Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.
    Cancer. 2017 Nov 3. doi: 10.1002/cncr.31065.
    PubMed     Abstract available


  164. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Abstract available


    October 2017
  165. KANTARJIAN HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, et al
    Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31082.
    PubMed     Abstract available


  166. TIRIBELLI M, Michelutti A, Fanin R, Damiani D, et al
    ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31037.
    PubMed    


  167. SHORT NJ, Kantarjian H, Jabbour E
    Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31036.
    PubMed    


  168. SHEN C, Zhao B, Liu L, Shih YT, et al
    Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31050.
    PubMed     Abstract available


    September 2017
  169. FATHI AT, Blonquist TM, Hernandez D, Amrein PC, et al
    Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31038.
    PubMed     Abstract available


  170. SCHEICH S, Lindner S, Koenig R, Reinheimer C, et al
    Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31045.
    PubMed     Abstract available


  171. BUCKLEY SA, Jimenez-Sahagun D, Othus M, Walter RB, et al
    Quality of life from the perspective of the patient with acute myeloid leukemia.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30982.
    PubMed     Abstract available


  172. PRINTZ C
    First person: Rudiger Hehlmann: The professor of medicine and founder of the European LeukemiaNet builds on his hard-won legacy of improving the survival rates of patients with leukemia.
    Cancer. 2017;123:3209-3210.
    PubMed    


    August 2017
  173. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Abstract available


    July 2017
  174. LEGROS L, Nicolini FE, Etienne G, Rousselot P, et al
    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30885.
    PubMed     Abstract available


  175. JAIN P, Kantarjian HM, Ghorab A, Sasaki K, et al
    Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30864.
    PubMed     Abstract available


  176. JABBOUR E, Short NJ, Ravandi F, Huang X, et al
    A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Cancer. 2017 Jul 14. doi: 10.1002/cncr.30883.
    PubMed     Abstract available


  177. ALVAREZ E, Keegan T, Johnston EE, Haile R, et al
    Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers.
    Cancer. 2017;123:2516-2523.
    PubMed     Abstract available


  178. MARINA NM, Liu Q, Donaldson SS, Sklar CA, et al
    Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.
    Cancer. 2017;123:2551-2560.
    PubMed     Abstract available


    June 2017
  179. ARIFFIN H, Azanan MS, Abd Ghafar SS, Oh L, et al
    Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging.
    Cancer. 2017 Jun 27. doi: 10.1002/cncr.30857.
    PubMed     Abstract available


  180. ZEIDAN AM, Hu X, Long JB, Wang R, et al
    Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30814.
    PubMed     Abstract available


  181. KANAGAL-SHAMANNA R, Jain P, Takahashi K, Short NJ, et al
    TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30810.
    PubMed     Abstract available


  182. RADICH JP
    Chronic myeloid leukemia: Global impact from a local laboratory.
    Cancer. 2017 Jun 6. doi: 10.1002/cncr.30776.
    PubMed    


    May 2017
  183. ALEXANDER TB, Wang L, Inaba H, Triplett BM, et al
    Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Cancer. 2017 May 30. doi: 10.1002/cncr.30791.
    PubMed     Abstract available


  184. LIN CJ, Vader JM, Slade M, DiPersio JF, et al
    Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
    Cancer. 2017;123:1800-1809.
    PubMed     Abstract available


  185. STAHL M, Zeidan AM
    Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Cancer. 2017;123:1703-1713.
    PubMed     Abstract available


  186. LEHMANN V, Tuinman MA, Keim MC, Winning AM, et al
    Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
    Cancer. 2017;123:1869-1876.
    PubMed     Abstract available


  187. MILLOT F, Dupraz C, Guilhot J, Suttorp M, et al
    Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30767.
    PubMed     Abstract available


  188. PERRY AM, Brunner AM, Zou T, McGregor KL, et al
    Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30639.
    PubMed     Abstract available


  189. MAURO MJ
    Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!
    Cancer. 2017 May 2. doi: 10.1002/cncr.30638.
    PubMed    


  190. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Abstract available


    April 2017
  191. CHEUNG YT, Brinkman TM, Mulrooney DA, Mzayek Y, et al
    Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2017 Apr 27. doi: 10.1002/cncr.30742.
    PubMed     Abstract available


  192. SEGAL E, Martens M, Wang HL, Brazauskas R, et al
    Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
    Cancer. 2017 Apr 27. doi: 10.1002/cncr.30737.
    PubMed     Abstract available


  193. KHOURY HJ, Collins RH Jr, Blum W, Stiff PS, et al
    Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
    Cancer. 2017 Apr 14. doi: 10.1002/cncr.30696.
    PubMed     Abstract available


  194. BATTIPAGLIA G, Ruggeri A, Massoud R, El Cheikh J, et al
    Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30680.
    PubMed     Abstract available


  195. BODDU PC, Kantarjian HM, Ravandi F, Garcia-Manero G, et al
    Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30704.
    PubMed     Abstract available


  196. NICOLINI FE, Basak GW, Kim DW, Olavarria E, et al
    Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30558.
    PubMed     Abstract available


    March 2017
  197. NAGLER A, Labopin M, Beelen D, Ciceri F, et al
    Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30646.
    PubMed     Abstract available


  198. RYTTING ME, Jabbour EJ, O'Brien SM, Kantarjian HM, et al
    Acute lymphoblastic leukemia in adolescents and young adults.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30624.
    PubMed     Abstract available


  199. YUCEL OK, Saliba RM, Rondon G, Ahmed S, et al
    Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning.
    Cancer. 2017 Mar 21. doi: 10.1002/cncr.30632.
    PubMed     Abstract available


  200. CHANG YJ, Wang Y, Mo XD, Zhang XH, et al
    Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30540.
    PubMed     Abstract available


    February 2017
  201. MANYAM BV, Garsa AA, Chin RI, Reddy CA, et al
    A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30601.
    PubMed     Abstract available



  202. First Person: Clara Bloomfield, MD.
    Cancer. 2017;123:369-370.
    PubMed    


    January 2017
  203. EL-JAWAHRI A, Chen YB, Brazauskas R, He N, et al
    Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    Cancer. 2017 Jan 19. doi: 10.1002/cncr.30546.
    PubMed     Abstract available


  204. PRINTZ C
    Device rapidly measures cell growth and can help determine drug resistance in cancer.
    Cancer. 2017;123:10-11.
    PubMed    


    September 2016
  205. RAO P, Li Y, Getz KD, Miller TP, et al
    Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.
    Cancer. 2016 Sep 12. doi: 10.1002/cncr.30225.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: